PAM
MRKR icon

Panagora Asset Management’s Marker Therapeutics MRKR Stock Holding History

Panagora Asset Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-74
Closed -$1K – 2882
2020
Q4 		$1K Hold
74
– – ﹤0.01% 2727
2020
Q3 		$1K Buy
+74
New +$1.35K ﹤0.01% 2651
2017
Q1 		– Sell
-678
Closed -$23K – 2419
2016
Q4 		$23K Buy
+678
New +$31.6K ﹤0.01% 2195

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Panagora Asset Management's MRKR Position: Q1 2021 in Review

Panagora Asset Management sold out of Marker Therapeutics (MRKR) in Q1 2021, closing a stake of 74 shares — an estimated $1K sold.

Panagora Asset Management first reported a position in MRKR in Q4 2016 and held it in 3 quarters. The position peaked at $23K in Q4 2016. 74 funds tracked by Wall St. Rank hold MRKR as of Q1 2021.

  • Panagora Asset Management reported no remaining Marker Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Panagora Asset Management sold 74 Marker Therapeutics shares in Q1 2021, an estimated $1K.
  • Panagora Asset Management first reported a position in Marker Therapeutics in Q4 2016 and held it in 3 quarters.
  • Panagora Asset Management's Marker Therapeutics position peaked at $23K in Q4 2016.
  • 74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2021.

Based on Panagora Asset Management's 13F filing for Q1 2021, filed 12 May 2021.